Before and beyond trust: reliance in medical AI

Charalampia (Xaroula) Kerasidou 1, Angeliki Kerasidou 2, Monika Buscher 1, Stephen Wilkinson 2

ABSTRACT

Artificial intelligence (AI) is changing healthcare and the practice of medicine as data-driven science and machine-learning technologies, in particular, are contributing to a variety of medical and clinical tasks. Such advancements have also raised many questions, especially about public trust. As a response to these concerns there has been a concentrated effort from public bodies, policy-makers and technology companies leading the way in AI to address what is identified as a “public trust deficit”. This paper argues that a focus on trust as the basis upon which a relationship between this new technology and the public is built is, at best, ineffective, at worst, inappropriate or even dangerous, as it diverts attention from what is actually needed to actively warrant trust. Instead of agonising about how to facilitate trust, a type of relationship which can leave those trusting vulnerable and exposed, we argue that efforts should be focused on the difficult and dynamic process of ensuring reliance underwritten by strong legal and regulatory frameworks. From there, trust could emerge but not merely as a means to an end. Instead, as something to work in practice towards; that is, the deserved result of an ongoing ethical relationship where there is the appropriate, enforceable and reliable regulatory infrastructure in place for problems, challenges and power asymmetries to be continuously accounted for and appropriately redressed.

INTRODUCTION

Artificial intelligence (AI) is changing healthcare and the practice of medicine as data-driven science and machine-learning technologies, in particular, are contributing to a variety of medical and clinical tasks.1, 2 This is indicative of a broader structural shift in healthcare, as the increased digitisation of the sector is creating a complex and potentially lucrative clinical data ecosystem enabled by a new constellation of actors; namely global consumer technology corporations which now join the medical professionals, healthcare providers, pharmaceutical companies, manufacturers and regulators as another key player in the healthcare domain.3 In this landscape, new clinical–corporate alliances are being formed as clinicians come under pressure to use valuable resources such as clinical data for better, cheaper, more efficient health services, while the corporations are seeking opportunities to establish themselves in (and arguably profit from) this growing market.4

However, such alliances also raise concerns as commercial data initiatives and scandals continue to hit the headlines.5, 6 In policy circles, in particular, these concerns have attracted a focus on trust, with many hoping that fostering public trust would dispel them and make it easier for AI technology to be accepted.8–10 Governments, advocacy groups and other national and international organisations are putting together guidelines and codes of ethics for AI governance in an effort to engender public confidence.11 For example, the European Commission places trust at the heart of its framework for Trustworthy AI, seeking to foster confidence in the technology’s development and applications by identifying trust as ‘the bedrock of societies, communities, economies and sustainable development’.11

The UK’s National Health Service (NHS) has developed a code of conduct for AI that articulates the ethical principles that should guide data-driven care.12 The tech industry has also been an active participant in these attempts to foster trust, setting up ethics advisory boards and developing its own codes of conduct, in order to show that it takes ethics seriously and bolster AI’s trustworthiness.13

Efforts to develop ethical principles and governance of AI have arguably foregrounded ethics as an important way of addressing the issue of public trust.14 However, their effectiveness to engender trust is questionable, while their largely voluntary nature ignores the reasons why governance is needed in the first place. In this paper, we challenge this focus on trust. Drawing broadly from philosophy, we understand trust as a type of relation that cannot merely be required, prescribed or coaxed.14 It should be freely given and, in putting one’s trust in another, one makes oneself vulnerable and dependent on the goodwill of the trustee. Trust occurs when one feels reasons to trust.16–18 As things stand, the public has little evidence that reasons to trust these new actors exist and that their long-voiced concerns are taken seriously. As such, we argue that a focus on trust as the basis on which a relationship between this new technology and the public is built is, at

We understand AI not as a stand-alone tool, but as a sociotechnical construct which brings together the social, technical, regulatory, ethical, political, imaginary.15

The organisation Algorithm Watch is in the process of compiling an AI Ethics Guidelines Global Inventory which currently counts more than 90 such sets https://inventory.algorithmwatch.org/ [Accessed 29 Apr 2021]

For example, Microsoft and Google have developed principles for ethical AI, and along with Amazon and Facebook were some of the founding members of the Partnership on AI to benefit People and Society. In 2016, DeepMind Health appointed an Independent Review Panel to scrutinise their work with the NHS. The panel was later disbanded after the company’s controversial take over by Google Health.

One can talk about trust between individuals -personal trust-, or between groups or collectives such as companies and institutions, institutional, apersonal or impersonal trust. As Kerasidou argues, in so far as a trust relationship is between two moral actors, being individuals or collectives/institutions, the type of relational trust we describe here applies.21

We do not have a table of contents. Please provide the sections you are interested in.
best, ineffective, at worst, inappropriate as it diverts attention from what is needed to actively warrant trust. By fixating on “improving” or “maintaining” trust in AI, policy-makers and technology developers are failing to provide reasons to trust and risk leaving the public vulnerable to Big Tech companies that are entering the health care space without evidence of their trustworthiness and commitment to the public good, and a clear course of holding them accountable if and when things go wrong. Instead, we argue that efforts should be focused on the difficult and dynamic process of ensuring reliance. Although in everyday language, trust and reliance are sometimes used interchangeably, there is a clear normative distinction between the two. Whereas trust normally denotes a relationship underpinned by the trustee’s goodwill towards the trustee, reliance is about ensuring predictability of behaviour. In the context of AI in healthcare, reliance can be underwritten by strong legal and regulatory frameworks that protect the public and ensure fair collaborations that serve the public good. From there, trust could emerge but not merely as a means to an end. Instead, as something to work in practice towards; that is, the deserved result of an ongoing ethical relationship where there is the appropriate, enforceable and reliable regulatory infrastructure in place for problems, challenges and power asymmetries to be continuously accounted for and appropriately redressed.

**PUBLIC (DIS)TRUST**

It is often stated as a fact that there is a crisis of public trust in AI which risks putting in danger the promise of AI in healthcare by ‘stifling innovation’ and resulting in unnecessary ‘opportunity costs’. For example, in 2018, the House of Lords report on AI in the UK stressed that ‘Maintaining public trust over the safe and secure use of their data is paramount to the successful widespread deployment of AI and there is no better exemplar of this than personal health data’. In 2019, UK’s Secretary of State, Matt Hancock, and the Minister for Innovation, Baroness Blackwood, highlighted trust—underlined by ‘ethics, transparency and the founding values of the NHS’—as the key to UK’s healthcare AI policy success. And writing for The Lancet in 2019, Morley, Taddeo and Floridi identify a ‘deficit of trust’ as the ‘fundamental problem’ to ‘unlocking’ the opportunities that collaborations such as that between Google Health and the NHS can achieve.

To date, few studies have been conducted to gauge the views of the public on the use of AI in sectors such as healthcare. Those that exist reveal a complex picture with responses that are thoughtful, pragmatic and largely positive. For example, a 2017 survey conducted on behalf of The Royal Society found that its participants were ‘highly positive’ about machine learning’s potential in the health sector. Also, a key finding of a 2018 report prepared for the Academy of Medical Sciences which asked members of the public, patients and healthcare professionals about their views on future data-driven technologies was that ‘There is optimism about new technology in healthcare. Participants felt new technologies in general could increase efficiency, improve success rates of diagnoses and save administrative and diagnostic time meaning clinicians could spend more time on patient care.’

Besides this optimism regarding the potential benefits of AI, these surveys also foreground questions and concerns on the opaque relationship that is being developed between public–private stakeholders, the danger of profit-motivated and of commercial interests clashing with the ethical values of healthcare and the need for appropriate regulation to carefully govern these new partnerships. These concerns, and associated calls for more regulation, are not new. For example, in 2013 when the now infamous case of care.data—an English initiative designed to allow the repurposing of primary care medical data for research and other purposes—occurred, issues such as the increasing commercialisation of healthcare, doubts over the new commercial partners’ commitment to the public good, and concerns over the loss of privacy when private actors enter the landscape, were also raised by the public. The project ended up being rejected and withdrawn.

Since then, care.data is often cited as a cautionary tale about the importance of public trust and the costly danger of losing it. However, this is only half of the story. As subsequent studies have shown, the other half is that people’s views were not ‘taken seriously’. Public trust cannot be coaxed with narrowly focused public relations exercises that merely seek to ‘capture’ the public; namely convince them of the legitimacy of decisions already taken for them rather than with them. Socio- logical research has demonstrated that the public’s relationship with science and technology is too complex to be characterised by a simple trust/distrust relationship, and the aforementioned studies confirm that. Past research has shown that science policy strategies that insist on addressing the “crisis of public trust” by trying to improve trust using top-down strategies such as informing/educating/communicating but without seriously engaging with and addressing the institutional reasons that led to public distrust, are condemned to repeat the same mistakes. Echoing Banner’s words, public trust is often cited as a cornerstone of better data use in the NHS and beyond, yet unless we address the conditions necessary for creating an environment worthy of trust in this new clinical-data ecosystem, it will remain elusive.

**TRUST AND ETHICAL CODES**

Fears of a deficit of public trust along with the host of ethical concerns that these new technologies introduce have triggered a surge of investment into ethical AI by governments, tech companies and other national and international organisations. This proliferation of principles, codes of ethics and practice, and PR campaigns has arguably foregrounded ethics and its importance. However, they are not without criticism. Many caution against their limitations, such as the difficulty of translating abstract ethical principles into the practical guidance needed by designers to address particular use cases and applications. Furthermore, reports show that the effectiveness of voluntary codes and guidelines is minimal as they fail to change the practices of tech professionals. As O’Neil argues, ethics governance practices and principles, such as confidentiality or consent do not confirm trust, but rather presuppose it. On this view, unless the companies who develop AI technologies are already seen as trustworthy, codes of conduct and ethical guidelines will not provide sufficient reasons to trust. Floridi also notes that ethics as a form of regulation, including self-regulation, ’can only function in an environment of public trust and clear responsibilities more broadly.’ The implication for public trust is that ethical principles alone, without a clear relationship and a strong legal framework, cannot provide enough motivation for trust. So, trying to address this perceived trust deficit through the introduction of ethics rules

---

“Interestingly, similar initiatives launched in Scotland and Wales were less controversial and more successful. See McCartney’s account of why and how the devolved nations did things differently.”
and self-regulations is ineffective as it puts "the cart before the horse".

Some also argue that codes of conduct prescribe ethics in a narrow and formalised way, where concerns raised by the public fall outside an agenda already set by policy-makers and traditional medical ethics. Even more so, the largely voluntary nature of ethical codes of conduct ignores the reasons why they are needed in the first place. The strong oversight and accountability mechanisms that could evidence genuine ethical commitments and concretely address the public's concerns are not there. Furthermore, reports on Big Tech's powerful lobbying, and its monetary influence on the ethics debate lend further credibility to criticisms of "ethics-washing". This is a phenomenon that is strategically used (and abused), first, to lend credibility and signal the moral standing of a company within a landscape where ethics is deemed to be the 'hottest product in Silicon Valley's hype-cycle', and second, to divert attention from legal and regulatory forms of governance. While the former provides further reasons to question the trustworthiness of these new actors, the latter poses a particular problem for the healthcare sector which is traditionally governed by strict professional codes on safety and accountability, as it raises the question; what might we miss when attention is diverted from legal rules and regulations?

Even though these technologies are entering the healthcare sector, it is questionable whether we are ready to use them safely and ethically. In the UK, a country which seeks to become a world leader in health, a report which assessed the state of AI in the sector concluded that the NHS IT infrastructure is not fit for AI yet. In 2019, Eric Topol, who led the government-commissioned Topol Review in the UK, warned that the state of AI hype has far exceeded the state of AI science, and in 2020 he called for updated regulations, standards and pathways of transparency that will require, not just retrospective studies as is currently the case, but actual clinical trials to prove the safety of AI medical tools. The oft-claimed superiority of AI's diagnostic performance over that of doctors does not always hold when put under careful scrutiny. And others warn that we still lack a clear regulatory pathway for AI medical devices, and the necessary evaluations to check whether a new AI system in practice does more good than harm resulting in allowing unsafe technologies 'into the wild'. In Gould's words, the CEO of NHSX, who after meeting in 2020 with the UK's relevant AI regulators identified 'gaps, lots of regulators on the pitch, and a lack of clarity on both standards and roles', 'We aren't there yet'.

BEFORE AND BEYOND TRUST

Trust has been theorised across many disciplines without a consensus on its definition. Drawing broadly from philosophy we could say that trust relationships take the form of: A trusts B to x. A trusts B to perform a specific action x, when A, the trustor, could say that trust relationships take the form of: A trusts B to x. A trusts B to perform a specific action x, when A, the trustor, believes that B, the trustee, possesses the appropriate knowledge or is responded to with, 'Why should and how can I, until I have

cause to?' However, this is exactly what the public is asked to do with these corporate actors even after they have, times and again, expressed their reasons for not trusting. Furthermore, as the case of care.data demonstrates, asking people to trust, when they question whether they have good reasons to do so, can be counterproductive. This is because, given the opportunity, people will retreat from a situation that could make them dependent on or vulnerable to someone they consider of questionable trustworthiness.

This brings us to another basic characteristic of trust. In trust relationships, the trustee can become vulnerable to the trustee,oled and dependent on their goodwill. Vulnerability and the power imbalance it entails are at the heart of healthcare. As such, it is governed by strict professional codes and strong ethical commitments on safety, and clear, enforceable pathways to accountability. However, as Mittelstadt explains, while AI borrows from medical ethics for developing its own ethical frameworks, it lacks the "(1) common aims and fiduciary duties, (2) professional history and norms, (3) proven methods to translate principles into practice and (4) robust legal and professional accountability mechanisms of medicine." These existing legal, regulatory and ethical gaps mean that it is not yet clear what happens if and when things go wrong with AI in healthcare. For example, legal scholars demonstrate that due to the complexity and gaps in the existing English law that addresses liability in the use of AI for clinical decision making, the tech companies seem to be protected while clinicians become morally and legally answerable for the potential defects of the AI system they choose to use. Also, the recent controversy over Babylon Health's 'chatbot' triage service brings into question the openness and readiness of tech companies to address legitimate concerns about the safety of their AI health products, and highlights the legal and regulatory gap that exists over their use. By asking the public to trust AI, and as such the tech companies driving this innovation, what is asked of them is to accept the risk that these companies are free to decide whether they will confirm or betray public trust. But how could the public reasonably take such a position, when they feel that they don't yet have reasons to trust? It seems inappropriate to ask the public to accept that position of vulnerability. In this light, trust seems to be an inappropriate, if not a dangerous, basis on which to base our relationship to AI.

There is, however, another way to approach this relationship that could avoid the pitfalls of trust while addressing the public's concerns. We argue for reliance. Reliance can be understood as 'dependence based on the likely prediction of another's behaviour', and while some understand trust as comprising reliance, there is a clear normative distinction between the two. Whereas trust, and the related trustworthiness, denote a moral characteristic or attitude, reliance and reliability are about predictability of behaviour without any reference to moral commitments or values. A relationship of reliance is based on reasonable expectations, proven capacity, open communication and clear and enforceable systems of responsibility and accountability. When a
relationship of reliance breaks down, blame is sought externally.67 This is why, in contrast to trust where feelings of betrayal might be evoked, relationships of reliance necessitate clear pathways of responsibility and accountability. What ensures reliance is the presence of self-interest that secures the partner’s commitment to the relationship, including the desire to avoid loss or penalty.68

Of course, this is not to say that things cannot go wrong in relationships of reliance. The risk is always there considering that we rely on someone when it is necessary to do so.69 70 However, in contrast to trust, there is no emotionally invested acceptance of this risk. Instead, mechanisms such as formal rules, contracts, regulations and systems of accountability, devised, implemented and overseen by independent and accountable governments and supranational organisations, are expected to offset it, hence protecting the public good while offering reasonable and equitable benefits to all parties. A mandatory, coherent and enforceable legal and regulatory framework would redress the power asymmetries between partners, ensure predictability of behaviour and accountability, and help establish a successful relationship based on openness, competence and reliability.

CONCLUSION

This paper argues for a shift in AI debates from trust to reliance, making the case that we should not be distracted by a quest on how to trust AI technologies when we don’t know if we can rely on them yet. As Sheehan et al remind us, this is not a negative conclusion, but one that recognises the conflict and power imbalance between healthcare and commercial interests and, importantly, acknowledges the fact that such imbalances affect the rigour with which these technologies can be evaluated, regulated and introduced. Advocating for and insisting on appropriate and enforceable regulation neither ends the discussion nor closes down the ethical debate. As the case of care.data illustrates,29–31 what constitutes appropriate and acceptable regulation is not straightforward. So, how do we judge these new and evolving technologies to be sufficiently safe or not? How do we ensure continuous monitoring as these machine-learning algorithms adjust, train and learn, or when they are applied in practice? How do we ensure oversight but also factor in uncertainty and risk? How do we judge that there aren’t other, simpler, more transparent, and more robust solutions for the task at hand? It is important that these questions, and many like them,32–34 are debated and decided not just in healthcare but across the AI sector. From there, trust could emerge but not as a means to an end. Instead, as something to work in practice towards; that is, the desired result of an ongoing ethical relationship where there is the appropriate, enforceable and reliable regulatory infrastructure in place for problems, challenges and power asymmetries to be continuously accounted for and appropriately redressed. While important work has already started,35 it is still much to be done. Shifting our attention from trust to reliance will refocus the debate and allow us the space and time to carefully and publicly consider these urgent matters.

Contributors All listed names are coauthors.

Funding This work was supported by the Wellcome Trust (213622/2/18/Z).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Charalampos (Xaroula) Kerasidou http://orcid.org/0000-0002-9794-8492
Angeliki Kerasidou http://orcid.org/0000-0001-9344-3297
Monika Buscher http://orcid.org/0000-0002-5581-1033
Stephen Wilkinson http://orcid.org/0000-0002-4445-9553

REFERENCES

1. Hartman AV, Rajpurkar P, Haghpanahi M, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med 2019;25(1):65–9.

2. McKinney SM, Stienek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. Nature 2020;577(7788):89–94.

3. Trusty R. Europe’s policy of digital data: introduction to the special issue. Policy Stud 2020;41(5):439–46.

4. Sharon T. The Googlization of health research: from disruptive innovation to disruptive ethics. Per Med 2016;13(6):363–74.

5. Hodson H. Revealed: Google AI has access to huge haul of NHS patient data. New scientist. 2016. Available: https://www.newscientist.com/article/2086454-revealed-google-ai-access-tohuge-haul-of-nhs-patient-data/ [Accessed 29 Apr 2021].

6. Pilkington E. Google’s secret cache of medical data includes names and full details of millions—whistleblower. The Guardian. 2019. Available: https://www.theguardian.com/ technology/2019/nov/12/google-medical-data-project-nightingale-secret-transfer-us-health-information [Accessed 29 Apr 2021].

7. Helm T. Revealed: how drugs giants can access your health records. The observer, 2020. Available: https://www.theguardian.com/technology/2020/feb/08/fearexposedanonymous-nhs-patient-data [Accessed 29 Apr 2021].

8. WHO. Big data and artificial intelligence for achieving universal health coverage: an international consultation on ethics. Geneva: World Health Organization, 2018. Available: https://www.who.int/ethics/publications/big-data-artificial-intelligence-report/en/.

9. House Of Lords Select Committee. AI in the UK: ready, willing and able?. House of Lords. 2018. Available: https://publications.parliament.uk/pa/ld201719/ldselect/ldai/ 100/100.pdf [Accessed 29 Apr 2021].

10. Ross J, Webb C, Rahman F. Artificial Intelligence in healthcare. Academy of Medical Royal Colleges, 2019. Available: https://www.aomrc.org.uk/wp-content/uploads/2019/01/Artificial_intelligence_in_healthcare_0119.pdf [Accessed 16 Mar 2020].

11. Independent High-Level Expert Group on Artificial Intelligence. Ethics guidelines for trustworthy AI. Brussels: European Commission, 2019. Available: https://ec.europa.eu/futurum/en/ai-alliance-consultation [Accessed 29 Apr 2021].

12. Department of Health and Social Care. Code of conduct for data-driven health and care technology, 2019. Available: https://www.gov.uk/government/publications/codeof-conduct-for-data-driven-health-and-care-technology [Accessed 29 Apr 2021].

13. Jasanoﬀ S. The ethics of invention: technology and the human future. WW Norton & Company, 2016.

14. Jobin A, Jenca M, Yavena E. The global landscape of AI ethics guidelines. Nat Mach Intell 2019;1(9):389–99.

15. Samuel GN, Farsides B. Public trust and ‘ethics review’ as a commodity: the case of Genomics England Limited and the UK’s 100,000 genomes project. Med Health Care Philos 2018;21(2):159–68.

16. Baier A. Trust and antitrust. Ethics 1986;96(2):231–60.

17. Kerasidou A. Trust me, I’m a researcher!: the role of trust in biomedical research. Med Health Care Philos 2017;20(1):43–50.

18. Hawley K, Trust, distrust and commitment. Nôus 2014;48(1):1–20.

19. Powles J, Hodson H. Google DeepMind and healthcare in an age of algorithms. Health Technol 2017;7(4):351–67.

20. Smith H, Fotheringham K. Artificial intelligence in clinical decision-making: rethinking liability. Med Law Int 2020;20(2):131–54.

21. Kerasidou A. Trusting institutions in the context of global health research collaborations. In: Laurie G, Mitra A, eds. Cambridge Handbook of health research regulation. Cambridge University Press, 2021.

22. Floridi L. AI opportunities for healthcare must not be wasted. Health Management 2019;19(2):https://healthmanagement.org/chip/hospital/issuearticle/aioportunities-forhealthcaremustnotbewasted

23. Morley J, Taddeo M, Floridi L. Google Health and the NHS: overcoming the trust deficit. Lancet Digit Health 2019;1(8):e389.

24. Ipsos MORI. Public views of machine learning: findings from public research and engagement conducted on behalf of the Royal Society. Report. London: Royal Society, 2017. https://royalsociety.org/-/media/policy/projects/machine-learning/publications/public-views-of-machine-learning-ipsos-mori.pdf

25. Castell S, Robinson L, Ashford H. Future data-driven technologies and the implications for use of patient data. Report prepared for the Academy of medical sciences by Ipsos mori. 2018. Available: https://amedics.ac.uk/file-download/6616969 [Accessed 29 Apr 2021].
26 Hill EM, Turner EL, Martin RM, et al. "Let's get the best quality research we can": public awareness and acceptance of consent to use existing data in health research: a systematic review and qualitative study. *BMJ Med Res Methodol* 2013;13(1):1–10.

27 Iqoss M. Public dialogue workshops report prepared for the health research authority. 2007.

28 Hunn A. Survey of the general public: attitudes towards health research. Health Research Authority. 2013.

29 Carter P, Laurie GT, Dixon-Woods M. The social licence for research: why care.data ran into trouble. *J Med Ethics* 2015;41(5):404–9.

30 Sterkx S, Rakic V, Cooks, J, et al. ‘You hoped we would sleep walk into accepting the collection of our data’: controversies surrounding the UK care.data scheme and their wider relevance for biomedical research. *Med Health Care Philos* 2016;19(2):177–90.

31 McCartney M. Care.data: why are Scotland and Wales doing it differently? *BMJ* 2014;348:g1702.

32 Morley J, Floridi L. NHS AI Lab: why we need to be ethically mindful about AI for healthcare. Available at SSRN 3445421, 2019.

33 van Staa TP, Goldacre B, Buchan I, et al. Big health data: the need to earn public trust. *BMJ* 2016;354:i3636.

34 Wynne B. Public uptake of science: a case for institutional reflexivity. *Public Underst Sci* 1993(24):321–37.

35 Felt U, Wynne B. Taking European knowledge Society seriously. Report prepared for European Commission, Directorate-General for research and innovation, 2007. Available: https://ep.europa.eu/en/publication-detail/-/publication/5d0de7c7-2948-4e5f-aec7-1be1fe3c442 [Accessed 29 Apr 2021].

36 Hopkins H, Kinsella S, van Mil A. Foundations of fairness: views on uses of NHS patients' data and NHS operational data. Findings Report, 2020. Available: https://understandingpatientsdata.org.uk/sites/default/files/2020-03/Foundations%20of%20fairness-%20final.pdf [Accessed 29 Apr 2021].

37 Sloane M. Making artificial intelligence socially just: why the current focus on ethics is not enough. British politics and policy at LSE, 2018. Available: http://eprints.lse.ac.uk/91219/1/Sloane_Making-artificial-intelligence_Author.pdf [Accessed 29 Apr 2021].

38 Morley J, Floridi L, Kinsey, L, et al. From what to how: an initial review of publicly available AI ethical guidelines and research to translate principles into practices. *Sci Eng Ethics* 2020;26(4):141–68.

39 Winfield AFT, Jiriotka M. Ethical governance is essential to building trust in robotics and artificial intelligence systems. *Philos Trans A Math Phys Eng Sci* 2018;376(2133):20180085.

40 McHalema A, Smith, I, Murphy-Hill E. Does ACM's code of ethics change ethical decision making in software development?...Proceedings of the 2018 26th ACM Joint Meeting on European Software Engineering Conference and Symposium on the Foundations of Software Engineering, 2018:729–33.

41 Vakkun V, Kemell KX, Kultanan J. Ethically aligned design of autonomous systems: industry viewpoint and an empirical study, arXiv preprint arXiv 2019.

42 O'Neill A. Autonomy and trust in bioethics. Cambridge: Cambridge University Press, 2002.

43 Floridi L. Soft ethics: its application to the general data protection regulation and its implications for trust in technology. *Philos Technol* 2019;2(1):163–76.

44 Satirana A, Stewi-Grindneff M. Big Tech Turns Its Lobbyists Loose on Europe, Alarming Big-tech-versus-clinicians: the teeth of ethics. *J Med Ethics* 2020;368:m815.

45 Metcalf J, Moss E. Owning ethics: corporate logics, silicon Valley, and the institutionalization of ethics. *Social Research: An International Quarterly* 2019;86(2):449–76.

46 Black J, Murray AD. Regulating AI and machine learning: setting the regulatory agenda. *European journal of law and technology* 2019;10(3).

47 Ressèquer A, Rodrigues R. AI ethics should not remain toothless! A call to bring back the teeth of ethics. *Big Data & Society* 2020;7(2).

48 Wagner B. Ethics as an escape from regulation: from ethics-washing to ethics-shopping. Being profiling. *Cognit. ergo sum* 2018:1–7.

49 Netbon A, AHSMN. Artificial intelligence in health and care: results from a state of the nation survey, 2018. Available: https://wssexahsmn.org/rimg/news/ AHSN%20Network%20AI%20Report-1536078823.pdf [Accessed 29 Apr 2021].

50 Topol EJ. The Topol review: preparing the healthcare workforce to deliver the digital future, 2019. Available: https://topol.hee.nhs.uk/the-topol-review/ [Accessed 20 Jun 2021].

51 Topol EJ. High-Performance medicine: the convergence of human and artificial intelligence. *Nat Med* 2019;25(1):44–56.

52 Topol EJ. Welcoming new guidelines for AI clinical research. *Nat Med* 2020;26(9):1319–20.

53 Naginathan M, Chen Y, Lovejoy CA, et al. Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. *BMJ* 2020;368:m689.

54 Muehlener JU, Daniole P, Vokinger KN. Approval of artificial intelligence and machine-learning-based medical devices in the USA and Europe (2015–20): a comparative analysis. *Lancet Digit Health* 2021;3.

55 Spiegelhalter D. Should we trust algorithms? *Harvard Data Science Review* 2020;2(1).

56 Morley J, Floridi L, Goldacre B. The poor performance of apps assessing skin cancer risk. *BMJ* 2020;368:m428.

57 Gould M. Regulating AI in health and care [Internet]. NHS Digital Transformation Blog, 2020. Available: https://digital.nhs.uk/blog/transformation-blog/2020/regulating-ai-in-health-and-care [Accessed 01 Oct 2020].

58 D’Cruz J. Humble trust. *Philos Stud* 2019;176(4):933–53.

59 Adjukem A, lencen M, Vayena E. What is trust? Ethics and risk governance in precision medicine and personalized surgery. *Nat Med* 2020;368:m689.

60 Sellman D. Trusting patients, trusting nurses. *Nurs Philos* 2007;8(1):28–36.

61 Mittelstadt B. Principles alone cannot guarantee ethical AI. *Nat Mach Intell* 2019;1(1):501–7.

62 Lomas N. UK’s MHRA says it has ‘concerns’ about Babylon Health — and flags legal gap around triage chatbots. TechCrunch, 2021. Available: https://techcrunch.com/2021/03/05/uk-s-mhra-says-it-has-concerns-about-babylon-health-and-flags-legal-gap-around-triage-chatbots/?guccounter=1&gce_referrer=aHR0cDovL25hcGhtYWJvdXNlcmF0aW9uLmNvbS8&gce_referrer_signal=AQQAAAQGyXieSHE4t0ZDaU5mdFO2tudhde7j1p5tv/vz9_0pC94zAKz8RzzLwU2UxJkFR4bJLmu7k7W0Vr6Rv50Rs0D5LWl690oa-Ma5kis-E5DW134h6zreminder-v3g9WqKQXVdW9dRqU0VkWi22232kNhBt-HmMhqy2LR2qGzMAZ [Accessed 29 Apr 2021].

63 Iacobucci G. Row over Babylon’s chatbot shows lack of regulation. *BMJ* 2020;368:m815.

64 Kerassidou A. The role of trust in global health research collaborations. *Bioethics* 2019;33(4):495–501.

65 Smith C. Understanding trust and confidence: two paradigms and their significance for health and social care. *J Appl Philos* 2005;22(3):299–316.

66 Holton R. Deciding to trust, coming to believe. *Australas J Philos* 1994;72(1):63–76.

67 Thompson C. Trust without reliance. *Ethical Theory and Moral Practice* 2017;20(3):643–55.

68 Braun M, Bleher H, Hummel P. A Leap of Faith: Is There a Formula for "Trustworthy" AI? Hastings Center Report, 2021.

69 Sheehan M, Friens P, Balmer A, et al. Trust, trustworthiness and sharing patient data for research. *J Med Ethics* 2020. doi:10.1136/medethics-2019-106048. [Epub ahead of print: 18 May 2020].

70 Price WN, Nicholson II. Regulating black-box medicine. *Mich Law Rev* 2017;116(3):421.

71 Proposal for a regulation of the European Parliament and of the Council laying down HARMONISED rules on artificial intelligence (artificial intelligence act) and amending certain Union legislative acts, COM(2021)206 final. Available: https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1623331514975&uri=CELEX:3AS2021PC0206 [Accessed 20 Jun 2021].